Promising drug cocktail may stall aggressive prostate cancer

NCT ID NCT05171816

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding olaparib to standard abiraterone therapy can slow the growth of metastatic castration-resistant prostate cancer better than abiraterone alone. About 110 men who have not had chemotherapy or newer hormone drugs for this stage of cancer will participate. The main goal is to see how long the cancer stays under control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Research Site

Beijing, 100034, China
Research Site

Beijing, 100050, China
Research Site

Beijing, 100142, China
Research Site

Beijing, 100191, China
Research Site

Beijing, 100730, China
Research Site

Chongqing, 400038, China
Research Site

Guangzhou, 510180, China
Research Site

Guangzhou, 510515, China
Research Site

Guizhou, 550002, China
Research Site

Henan, 450008, China
Research Site

Hubei, 430030, China
Research Site

Hunan, 410008, China
Research Site

Hunan, 410013, China
Research Site

Jilin City, 130012, China
Research Site

Jilin City, 130021, China
Research Site

Liaoning, 110001, China
Research Site

Nanchang, 330006, China
Research Site

Nanjing, 2100008, China
Research Site

Ningbo, 315000, China
Research Site

Shanghai, 200032, China
Research Site

Shanghai, 200040, China
Research Site

Sichuan, 610041, China
Research Site

Sichuan, 610072, China
Research Site

Xi'an, 710061, China
Research Site

Zhejiang, 310009, China
Research Site

Zhejiang, 310014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.